Bellecapital’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $19M | Buy |
75,615
+8,728
| +13% | +$1.88M | 3.04% | 10 |
|
|
2026
Q1 | $14.5M | Buy |
66,887
+2,133
| +3% | +$473K | 2.62% | 13 |
|
|
2025
Q4 | $14.8M | Sell |
64,754
-1,089
| -2% | -$248K | 2.63% | 16 |
|
|
2025
Q3 | $15.2M | Buy |
65,843
+3,563
| +6% | +$726K | 2.46% | 16 |
|
|
2025
Q2 | $11.6M | Sell |
62,280
-282
| -0.5% | -$52.4K | 2.05% | 19 |
|
|
2025
Q1 | $13.1M | Sell |
62,562
-7
| -0% | -$1.36K | 2.59% | 14 |
|
|
2024
Q4 | $11.1M | Buy |
62,569
+4,631
| +8% | +$851K | 1.96% | 17 |
|
|
2024
Q3 | $11.4M | Buy |
57,938
+220
| +0.4% | +$41.1K | 2.27% | 14 |
|
|
2024
Q2 | $9.9M | Buy |
57,718
+1,959
| +4% | +$325K | 2.1% | 14 |
|
|
2024
Q1 | $10.2M | Sell |
55,759
-4,983
| -8% | -$859K | 2.24% | 14 |
|
|
2023
Q4 | $9.41M | Buy |
60,742
+1,007
| +2% | +$147K | 2.13% | 15 |
|
|
2023
Q3 | $8.9M | Sell |
59,735
-2,636
| -4% | -$387K | 2.23% | 13 |
|
|
2023
Q2 | $8.4M | Sell |
62,371
-326
| -0.5% | -$47.8K | 2.03% | 15 |
|
|
2023
Q1 | $9.99M | Sell |
62,697
-2,111
| -3% | -$323K | 2.49% | 9 |
|
|
2022
Q4 | $10.5M | Sell |
64,808
-1,827
| -3% | -$280K | 2.94% | 7 |
|
|
2022
Q3 | $8.94M | Sell |
66,635
-1,621
| -2% | -$233K | 2.73% | 7 |
|
|
2022
Q2 | $10.5M | Sell |
68,256
-4,954
| -7% | -$757K | 2.92% | 6 |
|
|
2022
Q1 | $11.9M | Buy |
73,210
+5,151
| +8% | +$748K | 3.76% | 3 |
|
|
2021
Q4 | $9.21M | Buy |
68,059
+3,687
| +6% | +$436K | 2.63% | 7 |
|
|
2021
Q3 | $6.94M | Buy |
64,372
+1,340
| +2% | +$153K | 2.12% | 10 |
|
|
2021
Q2 | $7.1M | Sell |
63,032
-5,902
| -9% | -$665K | 2.16% | 10 |
|
|
2021
Q1 | $7.46M | Buy |
68,934
+5,524
| +9% | +$591K | 2.33% | 11 |
|
|
2020
Q4 | $6.79M | Buy |
63,410
+3,473
| +6% | +$334K | 2.27% | 12 |
|
|
2020
Q3 | $5.25M | Buy |
59,937
+4,913
| +9% | +$463K | 2.4% | 10 |
|
|
2020
Q2 | $5.4M | Sell |
55,024
-353
| -0.6% | -$31.1K | 2.53% | 11 |
|
|
2020
Q1 | $4.22M | Buy |
55,377
+5,944
| +12% | +$506K | 2.7% | 11 |
|
|
2019
Q4 | $4.38M | Buy |
49,433
+4,669
| +10% | +$388K | 2.24% | 13 |
|
|
2019
Q3 | $3.39M | Buy |
44,764
+667
| +2% | +$45.7K | 2.03% | 15 |
|
|
2019
Q2 | $3.21M | Sell |
44,097
-4,397
| -9% | -$346K | 1.99% | 17 |
|
|
2019
Q1 | $3.91M | Buy |
48,494
+505
| +1% | +$41.3K | 2.49% | 15 |
|
|
2018
Q4 | $4.42M | Buy |
47,989
+236
| +0.5% | +$20.8K | 3.15% | 14 |
|
|
2018
Q3 | $4.52M | Sell |
47,753
-3,047
| -6% | -$289K | 2.96% | 15 |
|
|
2018
Q2 | $4.71M | Buy |
50,800
+19,798
| +64% | +$1.93M | 3.4% | 12 |
|
|
2018
Q1 | $2.93M | Sell |
31,002
-7,843
| -20% | -$862K | 2.74% | 16 |
|
|
2017
Q4 | $3.76M | Buy |
38,845
+30,242
| +352% | +$2.85M | 3.04% | 15 |
|
|
2017
Q3 | $764K | Sell |
8,603
-813
| -9% | -$61.9K | 0.9% | 30 |
|
|
2017
Q2 | $683K | Sell |
9,416
-388
| -4% | -$26.1K | 0.6% | 35 |
|
|
2017
Q1 | $639K | Sell |
9,804
-750
| -7% | -$47.2K | 0.59% | 38 |
|
|
2016
Q4 | $661K | Sell |
10,554
-536
| -5% | -$32.7K | 0.59% | 36 |
|
|
2016
Q3 | $694K | Buy |
11,090
+1,450
| +15% | +$93.9K | 0.77% | 30 |
|
|
2016
Q2 | $573K | Buy |
+9,640
| New | +$587K | 0.63% | 33 |
|
Other funds holding ABBV
Bellecapital's ABBV Position: Q2 2026 in Review
Bellecapital increased its AbbVie (ABBV) stake by 13% in Q2 2026, buying an estimated $1.88M and bringing the position to 75,615 shares worth $19M. The position accounts for 3.04% of the portfolio, ranked #10.
Bellecapital first reported a position in ABBV in Q2 2016 and has held it in 41 quarters since. 4,190 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Bellecapital held 75,615 shares of AbbVie worth $19M as of Q2 2026.
- Bellecapital bought 8,728 AbbVie shares in Q2 2026, an estimated $1.88M.
- AbbVie made up 3.04% of Bellecapital's portfolio in Q2 2026, its #10 holding.
- Bellecapital first reported a position in AbbVie in Q2 2016 and has held it in 41 quarters since.
- 4,190 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Bellecapital's 13F filing for Q2 2026, filed 22 Jul 2026.